The sole purpose for their existence is to provide support when needed for Cramer's hedge fund buddies. In other words: unbridled manipulation.
Potential new investor here. Thanks for all of the information!
When is the MRI data due out or expected? This quarter? First half of year? TIA!
We will break through the psychological $5 barrier shortly.
Count on it!
Just a thought.
Form 8-K for IDERA PHARMACEUTICALS, INC.
Entry into a Material Definitive Agreement, Other Events, Financial S
Item 1.01. Entry into a Material Definitive Agreement
On February 12, 2015, Idera Pharmaceuticals, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Goldman, Sachs & Co. and J.P. Morgan Securities LLC, as representatives of the several underwriters (collectively, the "Underwriters"), related to an underwritten public offering of 20,000,000 shares of the Company's common stock, par value $0.001 per share (the "Common Stock"). The public offering price for the Common Stock is $3.75 per share. The underwriters have agreed to purchase the shares pursuant to the Underwriting Agreement at a price of $3.525 per share. The Company has also granted to the Underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock at the same price per share. All of the shares in the offering are to be sold by the Company.
The Common Stock will be issued pursuant to a prospectus supplement dated February 12, 2015 and an accompanying base prospectus dated May 22, 2014 that form a part of the registration statement on Form S-3 that the Company filed with the Securities and Exchange Commission, which became effective May 22, 2014 (File No. 333-195896). The Company expects that the closing of the sale of the Common Stock will take place on February 19, 2015, subject to the satisfaction of customary closing conditions.
A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to Exhibit 1.1.
A copy of the legal opinion and consent of Wilmer Cutler Pickering Hale and Dorr LLP relating to the validity of the Common Stock to be issued in the offering is attached as Exhibit 5.1 hereto.
Item 8.01. Other Even
J&E, in just a few paragraphs, how would you compare and contrast ADXS and ZIOP from a technical solution perspective and from a business perspective (e.g. PPS appreciation potential). TIA!
I couldn't get over how much it was posted time and time and time again.
The biggest pump I think I've ever seen. Ever!
2/16/15 -- From his mailbag this morning:
"Advaxis didn't misstate clinical trial results. You're reading too much into my column if you believe I hyped the company's stock or its cancer immunotherapy pipeline. I wrote about Advaxis' chief medical officer joining from Merck and the company's partnership with the Big Pharma giant because I thought these aspects of the bull thesis were over-looked and potentially meaningful."
The only blood we see is yours.
And guess what?
It's not green! LMAO!